Terms: = Lymphoma AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Diagnosis
33 results:
1. Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada.
Judd S; Revon-Riviere G; Grover SA; Deyell RJ; Vanan MI; Lewis VA; Pecheux L; Zorzi AP; Goudie C; Santiago R; Tran TH; Abbott LS; Brossard J; Moorehead P; Alvi S; Portwine C; Denburg A; Whitlock JA; Cohen-Gogo S; Morgenstern DA
Cancer Med; 2024 Feb; 13(3):e7033. PubMed ID: 38400668
[TBL] [Abstract] [Full Text] [Related]
2. The gene expression profile and cell of origin of canine peripheral T-cell lymphoma.
Owens E; Harris L; Harris A; Yoshimoto J; Burnett R; Avery A
BMC Cancer; 2024 Jan; 24(1):18. PubMed ID: 38166662
[TBL] [Abstract] [Full Text] [Related]
3. Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma.
Gao F; Liu H; Meng X; Liu J; Wang J; Yu J; Liu X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Golchehre Z; Chavoshzadeh Z; He J; Zhang H; Wang X
Br J Haematol; 2023 Sep; 202(6):1151-1164. PubMed ID: 37455019
[TBL] [Abstract] [Full Text] [Related]
4. Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemia.
Sarno J; Domizi P; Liu Y; Merchant M; Pedersen CB; Jedoui D; Jager A; Nolan GP; Gaipa G; Bendall SC; Bava FA; Davis KL
Nat Commun; 2023 May; 14(1):2935. PubMed ID: 37217509
[TBL] [Abstract] [Full Text] [Related]
5. KIF23 is a potential biomarker of diffuse large B cell lymphoma: Analysis based on bioinformatics and immunohistochemistry.
Gong Y; Zhou L; Ding L; Zhao J; Wang Z; Ren G; Zhang J; Mao Z; Zhou R
Medicine (Baltimore); 2022 Jun; 101(24):e29312. PubMed ID: 35713434
[TBL] [Abstract] [Full Text] [Related]
6. The utility of cerebrospinal fluid-derived cell-free DNA in molecular diagnostics for the
Chen WL; Pao E; Owens J; Glass I; Pritchard C; Shirts BH; Lockwood C; Mirzaa GM
Cold Spring Harb Mol Case Stud; 2022 Apr; 8(3):. PubMed ID: 35483878
[TBL] [Abstract] [Full Text] [Related]
7. Either IL-7 activation of JAK-STAT or BEZ inhibition of PI3K-AKT-mtor pathways dominates the single-cell phosphosignature of
Kuzilková D; Bugarin C; Rejlova K; Schulz AR; Mei HE; Paganin M; Biffi A; Biondi A; Kalina T; Gaipa G
Haematologica; 2022 Jun; 107(6):1293-1310. PubMed ID: 34670357
[TBL] [Abstract] [Full Text] [Related]
8. Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma.
Calimeri T; Steffanoni S; Foppoli M; Ponzoni M; Ferreri AJM
Expert Opin Ther Targets; 2021 Sep; 25(9):749-760. PubMed ID: 34606736
[No Abstract] [Full Text] [Related]
9. Novel therapeutic approaches for cutaneous T cell lymphomas.
Pavlidis A; Piperi C; Papadavid E
Expert Rev Clin Immunol; 2021 Jun; 17(6):629-641. PubMed ID: 33890833
[No Abstract] [Full Text] [Related]
10. Proteomic and transcriptomic studies of BGC823 cells stimulated with Helicobacter pylori isolates from gastric MALT lymphoma.
Zou Q; Zhang H; Meng F; He L; Zhang J; Xiao D
PLoS One; 2020; 15(9):e0238379. PubMed ID: 32915799
[TBL] [Abstract] [Full Text] [Related]
11. Epstein-Barr virus-associated smooth muscle tumor in a kidney transplant recipient: A case-report and review of the literature.
Tardieu L; Meatchi T; Meyer L; Grataloup C; Bernard-Tessier A; Karras A; Thervet E; Lazareth H
Transpl Infect Dis; 2021 Feb; 23(1):e13456. PubMed ID: 32881184
[TBL] [Abstract] [Full Text] [Related]
12. miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway.
Lucafò M; Sicari D; Chicco A; Curci D; Bellazzo A; Di Silvestre A; Pegolo C; Autry R; Cecchin E; De Iudicibus S; Collavin L; Evans W; Decorti G; Stocco G
Cancer Chemother Pharmacol; 2020 Sep; 86(3):361-374. PubMed ID: 32776229
[TBL] [Abstract] [Full Text] [Related]
13. [Expression of p-AKT and p-mtor in pediatric Burkitt lymphoma and their correlation with prognosis].
Man J; Chen L; Zhai XW; Ma YY; Wang HS; Qian XW; Feng JY; Zhao J; Cao P; Lu FJ
Zhonghua Bing Li Xue Za Zhi; 2020 Feb; 49(2):156-161. PubMed ID: 32074729
[No Abstract] [Full Text] [Related]
14. Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia.
James AR; Schroeder MP; Neumann M; Bastian L; Eckert C; Gökbuget N; Tanchez JO; Schlee C; Isaakidis K; Schwartz S; Burmeister T; von Stackelberg A; Rieger MA; Göllner S; Horstman M; Schrappe M; Kirschner-Schwabe R; Brüggemann M; Müller-Tidow C; Serve H; Akalin A; Baldus CD
J Hematol Oncol; 2019 Jan; 12(1):8. PubMed ID: 30642353
[TBL] [Abstract] [Full Text] [Related]
15. Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse.
Good Z; Sarno J; Jager A; Samusik N; Aghaeepour N; Simonds EF; White L; Lacayo NJ; Fantl WJ; Fazio G; Gaipa G; Biondi A; Tibshirani R; Bendall SC; Nolan GP; Davis KL
Nat Med; 2018 May; 24(4):474-483. PubMed ID: 29505032
[TBL] [Abstract] [Full Text] [Related]
16. Treatment of post-transplantation lymphoproliferative disorders after kidney transplant with rituximab and conversion to m-TOR inhibitor.
Nieto-Rios JF; Gómez de Los Ríos SM; Serna-Higuita LM; Ocampo-Kohn C; Aristizabal-Alzate A; Gálvez-Cárdenas KM; Zuluaga-Valencia GA
Colomb Med (Cali); 2016 Dec; 47(4):196-202. PubMed ID: 28293043
[TBL] [Abstract] [Full Text] [Related]
17. T-cell acute lymphoblastic leukemia.
Raetz EA; Teachey DT
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):580-588. PubMed ID: 27913532
[TBL] [Abstract] [Full Text] [Related]
18. Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?
Iqbal J; Wilcox R; Naushad H; Rohr J; Heavican TB; Wang C; Bouska A; Fu K; Chan WC; Vose JM
Blood Rev; 2016 Mar; 30(2):89-100. PubMed ID: 26319391
[TBL] [Abstract] [Full Text] [Related]
19. Post-transplant Lymphoproliferative Disorder: A Single-Center Experience.
Ferreira H; Bustorff M; Santos J; Ferreira I; Sampaio S; Salomé I; Bastos J; Bergantim R; Príncipe F; Pestana M
Transplant Proc; 2015 May; 47(4):981-4. PubMed ID: 26036499
[TBL] [Abstract] [Full Text] [Related]
20. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).
Launay-Vacher V; Aapro M; De Castro G; Cohen E; Deray G; Dooley M; Humphreys B; Lichtman S; Rey J; Scotté F; Wildiers H; Sprangers B
Ann Oncol; 2015 Aug; 26(8):1677-84. PubMed ID: 25735315
[TBL] [Abstract] [Full Text] [Related]
[Next]
